Rhythm Pharmaceuticals, Inc.   Report issue

For profit Phase 2 Phase 4
Founded: Boston MA United States (2008)

Organization Overview

First Clinical Trial
2012
NCT02431442
First Marketed Drug
2020
setmelanotide (Imcivree)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

RHYTHM | Rhythm Pharmaceuticals, Inc. | RHYTHM PHARMACEUTICALS INC | Rhythm Pharmceuticals, Inc | Rhythm Pharmceuticals, Inc.